Last reviewed · How we verify
Empagliflozin and Dulaglutide — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Empagliflozin and Dulaglutide (Empagliflozin and Dulaglutide) — Seoul National University Bundang Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Empagliflozin and Dulaglutide TARGET | Empagliflozin and Dulaglutide | Seoul National University Bundang Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Empagliflozin and Dulaglutide CI watch — RSS
- Empagliflozin and Dulaglutide CI watch — Atom
- Empagliflozin and Dulaglutide CI watch — JSON
- Empagliflozin and Dulaglutide alone — RSS
Cite this brief
Drug Landscape (2026). Empagliflozin and Dulaglutide — Competitive Intelligence Brief. https://druglandscape.com/ci/empagliflozin-and-dulaglutide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab